Structured evidence table for Glucosamine Joint Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Glucosamine Joint Health Randomized Trial | Meta-analyses were performed using random-effects models, and the GRADE methodology was applied to assess the certainty of the evidence. | 1 | Calzada-Gonzales N (2026) | Glucosamine supplementation in the treatment of temporomandibular joint disorders: a systematic review and meta-analysis. |
| Glucosamine Joint Health Randomized Trial | In patients with TMJ OA, compared with placebo, glucosamine may not result in a clinically important reduction in pain at ≤3 months (MD -1.58 mm; 95% CI -5.98 to 2.83; low certainty) and probably does not provide a clinically important reduction at 6 months despite statistical significance (MD -7.02 mm; 95% CI -11.95 to -2.09; moderate certainty). | 1 | Calzada-Gonzales N (2026) | Glucosamine supplementation in the treatment of temporomandibular joint disorders: a systematic review and meta-analysis. |
| Glucosamine Joint Health Randomized Trial | Glucosamine improved quality of life at 12 months (MD -4.14; 95% CI -6.41 to -1.87; high certainty). | 1 | Calzada-Gonzales N (2026) | Glucosamine supplementation in the treatment of temporomandibular joint disorders: a systematic review and meta-analysis. |
| Glucosamine Joint Health Randomized Trial | Background Glucosamine has been proposed as a therapeutic option for temporomandibular disorders (TMD), particularly temporomandibular joint osteoarthritis (TMJ OA), but its effectiveness and safety remain uncertain. | 1 | Calzada-Gonzales N (2026) | Glucosamine supplementation in the treatment of temporomandibular joint disorders: a systematic review and meta-analysis. |
| Glucosamine Joint Health Randomized Trial | This umbrella review synthesized evidence from published systematic reviews and meta-analyses on the effectiveness and safety of glucosamine in knee OA. | 3 | Li Y (2026) | Glucosamine for knee osteoarthritis: an umbrella review. |
| Glucosamine Joint Health Randomized Trial | Glucosamine was associated with significant slowing of JSN progression (SMD - 0.32, p = 0.01), though this signal derived mainly from long-duration sulfate trials. | 3 | Li Y (2026) | Glucosamine for knee osteoarthritis: an umbrella review. |
| Glucosamine Joint Health Randomized Trial | Conclusion Glucosamine demonstrated at most minimal-to-modest efficacy for knee OA, yielding a small pain reduction and possible slowing of radiographic progression but no clear functional benefit, with effects at or below the threshold of clinical importance. | 3 | Li Y (2026) | Glucosamine for knee osteoarthritis: an umbrella review. |
| Glucosamine Joint Health Randomized Trial | Background Knee osteoarthritis (OA) is a common cause of pain and disability without a cure. | 3 | Li Y (2026) | Glucosamine for knee osteoarthritis: an umbrella review. |
Source documents